64 related articles for article (PubMed ID: 18248380)
21. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
[TBL] [Abstract][Full Text] [Related]
22. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
Bräu N; Rodriguez-Torres M; Prokupek D; Bonacini M; Giffen CA; Smith JJ; Frost KR; Kostman JR
Hepatology; 2004 Apr; 39(4):989-98. PubMed ID: 15057903
[TBL] [Abstract][Full Text] [Related]
23. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
24. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
Kang MJ; Jung EU; Park SW; Choi P; Kim JH; Park SJ; Park ET; Lee YJ; Lee SH; Seol SY
Korean J Hepatol; 2008 Sep; 14(3):318-30. PubMed ID: 18815455
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
Fattovich G; Zagni I; Ribero ML; Castagnetti E; Minola E; Lomonaco L; Scattolini C; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Tomba A; Montanari R; Paternoster C; Distasi M; Fornaciari G; Tositti G; Rizzo C; Suppressa S; Pantalena M; Noventa F; Tagger A
J Viral Hepat; 2004 Nov; 11(6):543-51. PubMed ID: 15500555
[TBL] [Abstract][Full Text] [Related]
26. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
27. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
28. [Long-term viral response to interferon alpha 2b plus ribavirin in chronic hepatitis C patients during standard therapy].
Adamek A; Adamek J; Juszczyk J; Bereszyńska I
Przegl Epidemiol; 2007; 61(4):765-70. PubMed ID: 18572509
[TBL] [Abstract][Full Text] [Related]
29. The effect of cytokine profiles on the viral response to re-treatment in antiviral-experienced patients with chronic hepatitis C virus infection.
Zhang Y; Guo D; Zhao Y; Chen X; Ma L; Jin Y; Yan H; Wu H; Wei L; Dong T; Chen X
Antiviral Res; 2011 Nov; 92(2):247-54. PubMed ID: 21889543
[TBL] [Abstract][Full Text] [Related]
30. The Changed Proportion of CD45RA
Hsiao JL; Ko WS; Shih CJ; Chiou YL
J Interferon Cytokine Res; 2017 Jul; 37(7):303-309. PubMed ID: 28414566
[TBL] [Abstract][Full Text] [Related]
31. Eicosapentaenoic acid supplementation for chronic hepatitis C patients during combination therapy of pegylated interferon alpha-2b and ribavirin.
Kawashima A; Tsukamoto I; Koyabu T; Murakami Y; Kawakami T; Kakibuchi N; Takaguchi K; Kita K; Okita M
Lipids; 2008 Apr; 43(4):325-33. PubMed ID: 18320252
[TBL] [Abstract][Full Text] [Related]
32. Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirin.
Amati L; Caradonna L; Magrone T; Mastronardi ML; Cuppone R; Cozzolongo R; Manghisi OG; Caccavo D; Amoroso A; Jirillo E
Curr Pharm Des; 2002; 8(11):981-93. PubMed ID: 11945145
[TBL] [Abstract][Full Text] [Related]
33. Lower th-1/th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C.
Masaki N; Fukushima S; Hayashi S
Dig Dis Sci; 2002 Oct; 47(10):2163-9. PubMed ID: 12395887
[TBL] [Abstract][Full Text] [Related]
34. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.
Andreone P; Cursaro C; Gramenzi A; Margotti M; Ferri E; Talarico S; Biselli M; Felline F; Tuthill C; Martins E; Gasbarrini G; Bernardi M
J Viral Hepat; 2001 May; 8(3):194-201. PubMed ID: 11380797
[TBL] [Abstract][Full Text] [Related]
35. Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: a randomized controlled trial.
Motoo Y; Mouri H; Ohtsubo K; Yamaguchi Y; Watanabe H; Sawabu N
World J Gastroenterol; 2005 Jul; 11(26):4013-7. PubMed ID: 15996025
[TBL] [Abstract][Full Text] [Related]
36. Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C.
Langhans B; Nischalke HD; Arndt S; Braunschweiger I; Nattermann J; Sauerbruch T; Spengler U
PLoS One; 2012; 7(7):e42094. PubMed ID: 22848715
[TBL] [Abstract][Full Text] [Related]
37. Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level.
Enomoto S; Tamai H; Oka M; Shingaki N; Shiraki T; Takeuchi M; Deguchi H; Magari H; Inoue I; Iguchi M; Yanaoka K; Arii K; Fujishiro M; Yahagi N; Yotsuyanagi H; Ichinose M
Hepatol Res; 2007 Sep; 37(9):692-700. PubMed ID: 17573949
[TBL] [Abstract][Full Text] [Related]
38. Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial.
El-Darouti MA; Hegazy RA; Abdel Hay RM; El Hawary MS; Tawdy AM; Fawzy MM; Rashed LA
Arch Dermatol Res; 2015 May; 307(4):299-307. PubMed ID: 25450635
[TBL] [Abstract][Full Text] [Related]
39. Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C.
Ishii K; Sumino Y; Shinohara M; Higami K; Matsumaru K; Fujita Y; Sasao K; Wakui N; Shinohara M; Nagai H; Watanabe M; Miki K
Hepatol Res; 2006 Jan; 34(1):15-22. PubMed ID: 16293442
[TBL] [Abstract][Full Text] [Related]
40. Ribavirin in cancer immunotherapies: controlling nitric oxide helps generate cytotoxic lymphocyte.
Kast RE
Cancer Biol Ther; 2002; 1(6):626-30. PubMed ID: 12642684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
